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Background
Juvenile onset sondylarthropathy is a term that refers to
a group of human leucocyte antigen (HLA) -B27 asso-
ciated inflammatory disorders affecting children under
the age of 16 years.
The increased expression of tumor necrosis factor
alpha (TNF-alpha) in synovial tissue of patients with
juvenile onset and adults with active ankylosing spondy-
litis suggests a significant pathogenic role of TNF-alpha.
Objective
The authors present in an open label-pilot study the
efficacy and safety of TNF-alpha antagonists (etanercept,
adalimumab, infliximab) in 9 subjects with juvenile
onset spondylarthropathy.
Methods
Patients with Juvenile ankylosing spondylitis (JAS) trea-
ted with TNF-alpha blockers after failing NSAIDs and
DMARDs were evaluated in an open observational study
(2005-2011). At baseline patients and disease character-
istics were registered. Disease activity was evaluated
before the start of the treatment then after 3, 12, 24, 36,
48, 60 months by the application of Visual analogue
scale (VAS) for pain, Bath AS Disease Activity Index
(BASDAI), Erythrocite sedimentation rate (ESR) and the
functional ability by Bath AS Functional Index (BASFI).
Adverse events were documented.
Results
From 9 patients, (2-with adalimumab, 2- with infliximab,
5-with etanercept treatment), 5 were HLA- B27 positive,
mean age: 28 (21-40) years, one girl, mean age at onset of
disease: 12 (8-17) years, mean age at the diagnosis:
20 (18-26) years. All disease activity parameters improved
significantly in the first 3 months of treatments and
respectively with years. After 5 years 6 patients continued
the therapy. One side effect was observed.
Conclusions
Anti TNF alpha therapy is effective and well tolerated in
patients with JAS.
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